Ronald C Newbold Net Worth

What's Ronald Newbold's mailing address?

Ronald's mailing address filed with the SEC is 20 HILLCREST ROAD, , MARTINSVILLE, NJ, 08836.

Insiders trading at Celldex Therapeutics

Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil a Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.

What does Celldex Therapeutics do?

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im

Celldex Therapeutics executives and stock owners

Celldex Therapeutics executives and other stock owners filed with the SEC include:

• Ronald Pepin,
  Senior Vice President and Chief Business Officer
• Anthony Marucci,
  President, Chief Executive Officer, Director
• Anthony S. Marucci M.B.A.,
  Founder, Pres, CEO & Director
• Tibor Keler,
  Executive Vice President and Chief Scientific Officer
• Dr. Tibor Keler,
  Founder, Chief Scientific Officer & Exec. VP
• Dr. Diane C. Young M.D.,
  Sr. VP & Chief Medical Officer
• Margo Heath-Chiozzi,
  Senior Vice President - Regulatory Affairs
• Sam Martin,
  Chief Financial Officer, Senior Vice President, Secretary
• Richard Wright,
  Senior Vice President, Chief Commercial Officer
• Dr. Margo Heath-Chiozzi M.D.,
  Sr. VP of Regulatory Affairs
• Elizabeth Crowley,
  Senior Vice President, Chief Product Development Officer
• Sam Martin,
  Sr. VP, CFO, Sec. & Treasurer
• Elizabeth Crowley,
  Chief Product Devel. Officer & Sr. VP
• Karen Shoos,
  Independent Chairman of the Board
• Keith Brownlie,
  Independent Director
• James Marino,
  Independent Director
• Harry Penner,
  Independent Director
• Herbert Conrad,
  Independent Director
• Diane Young,
  Senior Vice President, Chief Medical Officer
• Sarah Cavanaugh,
  Senior Vice President - Corporate Affairs and Administration
• Prof. Joseph P. Schlessinger Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Dr. Richard M. Wright Ph.D.,
  Chief Commercial Officer & Sr. VP
• Dr. Ronald A. Pepin,
  Chief Bus. Officer & Sr. VP
• Freddy A. Jimenez Esq.,
  Sr. VP & Gen. Counsel
• Patrick Till,
  Sr. Director of Investor Relations & Corp. Communications
• Sarah Cavanaugh,
  Sr. VP of Corp. Affairs & Admin.
• Theresa La Vallee,
  SVP, Reg.& Precision Medicine
• Larry Ellberger,
  Director
• George Elston,
  Director
• Gerald Ph D Mc Mahon,
  Director
• Avery W Catlin,
  Sr. VP & CFO
• Den Broek Richard Van,
  Director
• Rita Jain,
  
• Timothy M Shannon,
  Director
• Rajesh B Parekh,
  Director
• Charles R Schaller,
  Director
• Inc Medarex,
  10% owner
• Ronald C Newbold,
  Sr. VP, Business Dev.
• Cheryl Cohen,
  
• Freddy A. Jimenez,
  SVP & GENERAL COUNSEL
• Garry Arthur Neil,